180 Life Sciences
Yahoo Finance • last year
180 Life Sciences Announces Review of Strategic Alternatives
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alter... Full story
Yahoo Finance • 2 years ago
180 Life Sciences Announces Presentation at the Gordon Conference
PALO ALTO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that Professor Jagdeep Nanchahal has been selected to present at the Gordon Research Conf... Full story
Yahoo Finance • 2 years ago
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial
PALO ALTO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced closure to recruitment of men and women across England with early stage Frozen shoulder f... Full story
Yahoo Finance • 2 years ago
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
PALO ALTO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company has engaged Kinexum, a strategic advisory firm, to support the Company i... Full story
Yahoo Finance • 2 years ago
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
PALO ALTO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on January 4, 2023 from The Nasdaq Stock Market LLC (“... Full story
Yahoo Finance • 2 years ago
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Dupuytren’s disease: a localized and accessible hum... Full story
Yahoo Finance • 2 years ago
180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan
PALO ALTO, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will effect a one-for-20 reverse stock split (“reverse split”) of its common stoc... Full story
Yahoo Finance • 2 years ago
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture
PALO ALTO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company and its regulatory consultants from the US and the UK, met with the UK M... Full story
Yahoo Finance • 2 years ago
Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today announced that researchers at Oxford Population Health’s Healt... Full story
Yahoo Finance • 2 years ago
180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder
PALO ALTO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first patient has been randomized in the clinic... Full story
Yahoo Finance • 3 years ago
180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease
PALO ALTO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs... Full story
Yahoo Finance • 3 years ago
180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren’s Disease
PALO ALTO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs... Full story
Yahoo Finance • 3 years ago
REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 months The treatment arm showed that nodules continued to soften a... Full story
